AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 162 min read$BIVI

RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.

Original reporting
finanznachrichten.de
Published Sep 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$BIVI
Bullish
high confidence
Mentioned
$BIVI
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

The data could catalyze a short‑term rally, but long‑term valuation depends on subsequent Phase 3 results and FDA review.

02

Market read

First disclosure of Phase 2 results for a micro‑cap biotech, likely to move BIVI stock and influence related neuro‑inflammation stocks.

03

What to watch

Regulatory timeline and competition from other Long COVID candidates.

Relevance 8/10Novelty 8/10Timing: today

Background

The release announces a live investor webinar and presents the first public readout of BioVie's Phase 2 trial for bezisterim.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie disclosed Phase 2 ADDRESS-LC trial results, with 21 of 22 endpoints favoring bezisterim for Long COVID.

Expected impact

Potential upside of 10‑15% over the next weeks if data holds up.

Evidence & confidence

Phase 2 success in a micro‑cap biotech often triggers speculative buying ahead of further trials.

Market effects

Sector

Positive data may lift other neuro‑inflammation biotech peers.

Regional

Limited to US and biotech‑focused investors.

Global

Adds to broader interest in Long COVID therapeutics.

Counterpoint

What could challenge this read

Phase 2 success does not guarantee Phase 3 outcomes; risk of over‑optimism.

Key entities

  • company
    BioVie Inc.

    Clinical‑stage biopharma developing bezisterim for neuro‑inflammatory conditions.

  • service_provider
    RedChip Companies, Inc.

    Investor‑relations firm hosting the webinar.

Read at source← All news

Related articles

SEP 15
$BIVIMedAI 8/10

BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases

BioVie Inc. reported Phase 2 trial results for bezisterim, showing statistically significant symptom improvements in severe Long COVID patients with high baseline disease burden. The 203-patient trial evaluated 22 clinical outcomes and biomarkers. Subgroup analyses showed significant improvements in fatigue, cognitive impairment, and other symptoms. The company plans further Phase 3 trials to confirm these results. According to the company, bezisterim may become the first therapy for neurologica

proactiveinvestors.com2 min
SEP 15
$BIVIMedAI 8/10

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

rttnews.com2 min
SEP 15
$BIVIMedAI 9/10

BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) reported positive Phase 2 trial results for bezisterim, showing statistically significant benefits in Long COVID patients with high baseline fatigue, cognitive impairment, and post-exertional malaise. The drug outperformed placebo on 21 of 22 endpoints in these subgroups, with a safety profile similar to placebo. The company plans to discuss the results in a conference call today.

finanznachrichten.de2 min
SEP 8
$BIVIMed

BioVie advances Parkinson’s Phase 3 development program with FDA engagement

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

proactiveinvestors.com2 min
AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min